CN106110389A - A kind of moist dressing of skin wound and its preparation method and application - Google Patents
A kind of moist dressing of skin wound and its preparation method and application Download PDFInfo
- Publication number
- CN106110389A CN106110389A CN201610784318.2A CN201610784318A CN106110389A CN 106110389 A CN106110389 A CN 106110389A CN 201610784318 A CN201610784318 A CN 201610784318A CN 106110389 A CN106110389 A CN 106110389A
- Authority
- CN
- China
- Prior art keywords
- moist dressing
- sanguis draxonis
- skin wound
- wound
- dressing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0014—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Gastroenterology & Hepatology (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention belongs to medicines dressing field, it is specifically related to moist dressing of a kind of skin wound and preparation method thereof, described moist dressing it include following components: the Sanguis Draxonis of 0.05 0.3wt%, the epidermal growth factor of 0.0001 0.001wt%, the gel-type vehicle of 1 5wt%, the wetting agent of 2 10wt%, the penetrating agent of 0.5 5wt%, the antibacterial of 0.01 2wt%, surplus is water for injection.Moist dressing prepared by the present invention can improve local blood circulation, improves local nutritional status, promotes granulation tissue growth, accelerates wound healing, and clinical effectiveness is notable.
Description
Technical field
The invention belongs to medicines dressing field, be specifically related to moist dressing of a kind of skin wound and preparation method thereof.
Background technology
Skin wound the most forms ulcer, has several aspect reason: operative incision, the infection of wound surface, liquefaction of fat and
Varicose veins of the lower extremity.Wound healing is broadly divided into 4 and gradually occurs and overlapped processes, i.e. hemostasis, inflammatory reaction,
Breed, reinvent.The reparation of diabetic ulcer needs the blood supply of abundance and good wound healing environment.In recent years, no
Factors such as studies have found that wound surface tropic growth factors shortage and activity decrease of breaking is to cause the major reason of wound healing difficulty,
The ratio that every diabetics occurs ulcer in its life cycle is 15%.Diabetic ulcer once occurs, and treatment is very
Difficulty, easily forms chronic ulcer and relapse rate is high.Diabetic foot ulcer treatment emphasis: one be improve local blood circulation and
Nutrition, two is infection.
Past traditional Wound healing and bone regeneration principle is for being dried healing, it is simply that allows wound keep being dried incrustation, promotes wound healing,
Dry crusts is formed due to the evaporation of wound exudate, dressing easy adhesion wound surface, easily damages new granulation tissue, causes wound when changing dressings
Mouthful healing rate is slowly and patient pain.Now with the research and development of wound surface nursing, advocate wet union theoretical, it is believed that moist
Environment more readily promotes the healing of wound.When reason is wet union, being retained in the exudate of wound surface, to contain histone molten
Solve enzyme, promote slough and fibrinous dissolving, be conducive to absorbing and playing the effect of debridement.Wet environment is typically
Being formed under the dressing of closure, wound microenvironment is commonly formed low oxygen tensions, under relative low-oxygen environment, fibroblastic growth
Fastest and stimulating expression of macrophage discharges multiple somatomedin, accelerates vascularization, promotes that the formation of granulation tissue is the wettest
Property environment maintain the constant temperature of wound surface, be beneficial to tissue without incrustation healing, it is to avoid new granulation tissue's mechanicalness again is damaged
Wound, eases the pain.
Sanguis Draxonis has another name called Sanguis Draxonis, and Sanguis Draxonis is pure Chinese medicinal preparation, is containing of Liliaceae dracaena plant Dracaena cochinchinensis
Tallow wood material extracts the resin obtained, and has blood circulation promoting and blood stasis dispelling, reducing swelling and alleviating pain, astringing to arrest bleeding, hard masses softening and resolving and promoting tissue regeneration and ulcer healing etc. notable
Effect；Modern medicine study confirms that the Sanguis Draxonis Saponin contained in Sanguis Draxonis has obvious antibacterial analgesic activity；Plant defense
Element composition Han Progesterone, belongs to natural Antimicrobial preservative material, has removing the necrotic tissue and promoting granulation effect.Existing multinomial research confirms, sanguis draconis
Exhaust and the skin injurys such as diabetic foot ulcer, refractory skin wound, pressure ulcer are had the curative effect that well heals.Sanguis Draxonis powder is carried out ultra micro
Change processes so that it is particle diameter diminishes, and exposed area increases, and increases skin contact, and leachable increases, and improves curative effect.
Recombinant human epidermal growth factor is that a class has the biological activity such as vascularization promoting cell proliferation and differentiation and wound
Polypeptide or protein, repair in trauma is risen important regulating and controlling effect, the increasing of epithelial cell, fibroblast etc. can be obviously promoted
Grow, break up and migrate, promote new granulation tissue to be formed and the re-epithelialization of wound, accelerate the wound healing of skin histology.But
Recombinant human epidermal growth factor is without the effect of removing the necrotic tissue and promoting granulation, not good enough for the wound surface of a large amount of sloughs, and dragon's blood capsule by
Natural plant Chinese Folium Dracaenae cambodianae active ingredient develops, containing the various active compositions such as Sanguis Draxonis saponin and plant defense element, tool
Having antiinflammatory removing the necrotic tissue and promoting granulation, blood circulation promoting and blood stasis dispelling, dissipate pain hemostasia effect, both share and have given full play to removing the necrotic tissue and promoting granulation, promote organization healing
Effect, can improve local blood circulation, improve local nutritional status, promote granulation tissue growth, accelerate wound healing, clinical
Effect is obvious.
Summary of the invention
Invention broadly provides moist dressing of a kind of skin wound and preparation method thereof, the dressing of preparation can improve
Local blood circulation, improves local nutritional status, promotes granulation tissue growth, accelerates wound healing, and clinical effectiveness is notable.Its skill
Art scheme is as follows:
The moist dressing of a kind of skin wound, it includes the Sanguis Draxonis of following components: 0.05-0.3wt%, 0.0001-
The epidermal growth factor of 0.001wt%, the gel-type vehicle of 1-5wt%, the wetting agent of 2-10wt%, the penetrating agent of 0.5-5wt%,
The antibacterial of 0.01-2wt%, surplus is water for injection.
Preferably, described Sanguis Draxonis is Sanguis Draxonis superfine powder, and the particle diameter of described Sanguis Draxonis superfine powder is not more than 10 μm.
Preferably, described epidermal growth factor is in recombinant human epidermal growth factor and fibroblast growth factor
One or both, the mass concentration of described epidermal growth factor is 1000-10000IU/ml.
Preferably, described gel-type vehicle is in hydroxymethyl cellulose, hypromellose, carbomer and hyaluronic acid sodium
One or more.
Preferably, described wetting agent is glycerol and/or propylene glycol.
Preferably, one or more in propylene glycol, azone and carbamide of described penetrating agent.
Preferably, described antibacterial is selected from parabens, benzoic acid/sodium benzoate, quaternary ammonium salt-15, streptococcus acidi lactici
One or more in element and benzalkonium bromide.
Preferably, the pH of described moist dressing is 5.5-7.5, uses sodium hydroxide, hydrochloric acid, borate buffer or phosphoric acid to delay
Rush liquid regulation.
The preparation method of the moist dressing of a kind of skin wound, comprises the following steps:
(1) first use jet mill dry pulverization process Sanguis Draxonis, obtain coarse grain, then use ball mill dry grinding coarse grain,
Obtaining Sanguis Draxonis superfine powder particle diameter and be not more than 10 μm, dry powder is collected stand-by；
(2) measure the water for injection of formula ratio 40-50%, be heated to 70-90 DEG C, formula ratio gel-type vehicle is added it
In, stirring is until becoming gel-type vehicle；
(3) measure the water for injection of 40-50%, recipe quantity epidermal growth factor, wetting agent, penetrating agent, antibacterial are added
Enter wherein, stir；
(4) solution of preparation in (3) is poured in gel-type vehicle prepared by (2), add Sanguis Draxonis prepared by step (1)
Superfine powder, stirs and regulates pH to 5.5-7.5；
(4) supply water for injection, stir, fill, obtain moist dressing.
Use moist dressing of above-mentioned treatment skin ulcer and preparation method thereof, the invention have the advantages that
Epidermal growth factor is added, it is possible to promote skin tissue recovering, good biocompatibility, and Sanguis Draxonis energy in dressing
Make up the defect of growth factor for treating skin ulcer, after micronization processes, significantly improve drug effect, play efficient therapeutic effect；Solidifying
Gel matrix is network structure, and medicine dissolution wherein can pass through gel layer sustained release, extends drug treating time, keeps wound to exist
Under moist environment, beneficially wound healing, make wound to form a scab.The moist dressing of the present invention can be applied directly to wound table
Face, it is also possible to combine medical transparent pad pasting and gauze uses, prevent medicine to be washed off or wipe.
Detailed description of the invention
Embodiment 1
1. Sanguis Draxonis 0.17wt%, recombinant human epidermal growth factor 0.0004wt%, hydroxymethyl cellulose 1.7wt%, glycerol
2wt%, azone 0.5wt%, ethyl hydroxybenzoate 1wt%, 5%NaOH regulation pH are 6.0, and surplus is water for injection.
2. operational approach:
(1), temperature 20 DEG C, under conditions of relative humidity 45%, jet mill, dry pulverization process Sanguis Draxonis 1h, powder are used
Broken rear particle diameter about 10 μm, then ambient temperature 20 DEG C, under conditions of relative humidity 35%, uses ball mill, and rotating speed is
1000rpm/min dry grinding 5 times, grinds 5min every time, makes Sanguis Draxonis powder particle diameter collect stand-by less than 10 μm, dry powder；
(2) measure the water for injection of formula ratio 40% weight, be heated to 80 DEG C, recipe quantity hydroxymethyl cellulose is added it
In, lower the temperature while stirring, stir speed (S.S.) 200rpm, after being down to room temperature, it is gel-type vehicle；
(3) measure the water for injection of recipe quantity 50%, recipe quantity somatomedin, glycerol, azone, ethyl hydroxybenzoate are added
Wherein, stir；
(4) solution in (3) is poured in (2), adds recipe quantity Sanguis Draxonis powder, stir 20 minutes, add 5% sodium hydroxide or
Salt acid for adjusting pH is 6.0；
(5) supply water for injection, stir, fill, obtain moist dressing.
Embodiment 2
1. Sanguis Draxonis 0.3wt%, recombinant human epidermal growth factor 0.001wt%, hypromellose 5wt%, glycerol
5wt%, carbamide 2wt%, nisin 0.01wt%, 5%NaOH regulation pH are 7.0, and surplus is water for injection.
2. operational approach:
(1), temperature 10 DEG C, under conditions of relative humidity 25%, jet mill, dry pulverization process Sanguis Draxonis 1h, powder are used
Broken rear particle diameter about 10 μm, then ambient temperature 15 DEG C, under conditions of relative humidity 55%, uses ball mill, and rotating speed is
1200rpm/min dry grinding 4 times, grinds 6min every time, and Sanguis Draxonis powder particle diameter is less than 10 μm, and dry powder is collected stand-by；
(2) measure the water for injection of recipe quantity 60%, be heated to 90 DEG C, recipe quantity hypromellose is added thereto,
Lower the temperature while stirring, stir speed (S.S.) 300rpm, after being down to room temperature, it is gel-type vehicle；
(3) measure the water for injection of recipe quantity 40%, recipe quantity somatomedin, glycerol, azone, nisin are added
Enter wherein, stir；
(4) solution in (3) is poured in (2), adds recipe quantity Sanguis Draxonis powder, stir 20 minutes, add 5% sodium hydroxide or
Salt acid for adjusting pH is 7.0；
(5) stir, fill, obtain moist dressing.
Embodiment 3
1. Sanguis Draxonis 0.05wt%, recombinant human epidermal growth factor 0.0001wt%, carbomer 3wt%, glycerol 4wt%,
Propylene glycol 6wt%, sodium benzoate 2wt%, phosphate buffer regulation pH to 5.5, surplus is water for injection.
2. operational approach:
(1), temperature 10 DEG C, under conditions of relative humidity 65%, use jet mill, dry pulverization process Sanguis Draxonis 1h, pulverize
Rear particle diameter about 10 μm, then ambient temperature 30 DEG C, under conditions of relative humidity 55%, uses ball mill, and rotating speed is 700rpm/
Min dry grinding 6 times, grinds 2min every time, and Sanguis Draxonis powder particle diameter is less than 10 μm, and dry powder is collected stand-by；
(2) measuring the water for injection of recipe quantity 40%, be heated to 80 DEG C, be added thereto by recipe quantity carbomer, limit is stirred
Limit lowers the temperature, and stir speed (S.S.) 200rpm is gel-type vehicle after being down to room temperature；
(3) measure the water for injection of recipe quantity 40%, recipe quantity somatomedin, glycerol, propylene glycol, sodium benzoate are added
Wherein, stir；
(4) solution in (3) is poured in (2), add recipe quantity Sanguis Draxonis powder, stir 15 minutes, add phosphate buffer and adjust
Joint pH is 5.5；
(5) supply water for injection, stir, fill, to obtain final product.
Embodiment 4
1. Sanguis Draxonis 0.24, fibroblast growth factor 0.0008, hyaluronic acid sodium 2, propylene glycol 4, quaternary ammonium salt-15
0.07, borate buffer regulation pH value of solution is 7.5, and surplus is water for injection.
2. operating procedure:
(1), temperature 15 DEG C, under conditions of relative humidity 25%, use jet mill, dry pulverization process Sanguis Draxonis 1h, pulverize
Rear particle diameter about 10 μm, then ambient temperature 15 DEG C, under conditions of relative humidity 25%, uses ball mill, and rotating speed is 800rpm/
Min dry grinding 4 times, grinds 4min every time, and Sanguis Draxonis powder particle diameter is less than 10 μm, and dry powder is collected stand-by；
(2) measure the water for injection of recipe quantity 50%, recipe quantity hyaluronic acid sodium be added thereto, stir speed (S.S.) 1500rpm,
Until becoming gel-type vehicle；
(3) measure the water for injection of recipe quantity 40%, recipe quantity somatomedin, glycerol, propylene glycol, quaternary ammonium salt-15 are added
Enter wherein, stir；
(4) solution in (3) is poured in (2), add recipe quantity Sanguis Draxonis powder, stir 18 minutes, add 5 borate buffers and adjust
Joint pH is 7.5；
(5) supply water for injection, stir, fill, to obtain final product.
Pharmacodynamic experiment
One, preparation is investigated to rat wound surface injury repairing effect
1. sample: experimental group: according to the dressing sample of the present embodiment 1 preparation；Positive controls: somatomedin dressing (removes
Without Sanguis Draxonis, remaining prescription is with embodiment 1)；Negative control group: physiological saline solution.
2. animal: healthy adult SD rat 30, body weight 200-250g, male.
3. operation:
30 rats are randomly divided into 3 groups, each 10, numbering in group, respectively test group, positive controls, negative right
According to group.After 3 groups of rat abdomen injecting anesthetics, in both sides, back production machinery full thickness skin wound surface, wound surface diameter 2cm, in circle
Shape, deep and subcutaneous muscular fasciae, use sterile gauze hemostasis by compression.Test group and positive controls cover with corresponding moist dressing, outward
Layer aseptic dressing wrapping, matched group with 0.2mL normal saline be loaded into gauze flap coverage, the next day change.During modeling and after modeling
Within 3rd, 6,10,16 days, measure Wound healing rate, within after modeling the 3rd, 6 days, survey wound inflammation integration, during modeling and after modeling the 3rd, 6,
Within 10 days, take wound tissue for detecting I/ III Collagen Type VI ratio.1. Wound healing rate calculates: measure wound surface face with Image J software
Long-pending, by following equation calculating Wound healing rate: healing rate=[(original wound surface area-do not heal wound surface area)/original wound surface face
Long-pending] × 100%.2. wound inflammation integration: wound exudate character is divided into serum sample, serosity sample, muddy sample；Sepage amount is few
Amount, amount a small amount of, middle, a large amount of time be calculated as 1,2,3,4 points respectively, sepage amount observes with the number of plies being impregnated with gauze that (< 1 layer is few
Amount,>=1 layer but<4 layers be on a small quantity,>=4 layers but<8 layers is middle amount, and>=8 layers is a large amount of), wound healing is 0 point.3. wound surface I/ III
Collagen Type VI ratio measuring: collagen extraction uses acetic acid-acidity pepsin method, collagen detection to use enzyme-linked immunosorbent assay.
Statistical analysis: experiment the data obtained all withRepresenting, comparing group difference with t inspection, P≤0.05 is for poor
Different statistically significant.
4. result:
(1) each group Rat Wound Healing rate comparative result is shown in Table 1.
From result, treat the 3rd day, three groups of Wound healing rates i.e. have difference, test group healing rate be higher than other two
Group, clearly visible new capillary vessel, cell in its wound surface；Treating the 7th day, each group healing rate is all significantly improved, its pilot scale
Test group healing rate to 75%, edge of wound epitheliosis becomes apparent from, and in wound surface, granulation tissue increases, fibroblast and blood capillary
Number is more, and healing effect is obvious；Treating the 10th day, test group healing rate is to more than 90%, and wound surface new life epidermis cell is
Substantially covering wound, and visible obvious keratinization, positive controls wound surface collagen fiber are also significantly more than negative control group；Treatment the
16 days, test group substantially completely healed, and positive controls healing rate has reached 95% the most, is significantly higher than negative control group.
Table 1 different time Wound healing rate
Note: compare with negative control group, p < 0.01；Compare with positive controls, p < 0.05.
(2) each group rat wound inflammation integral contrast result fruit is shown in Table 2.
Treating the 3rd day, negative control group wound surface integration is higher, and mainly showing as wound surface has moderate serosity sepage, positive
Matched group and test group sepage are considerably less than negative control group, show as a small amount of serum solution sepage；Treat the 7th day, respectively organize wound surface
Sepage amount all substantially reduces, and negative control group still has part wound exudate to be serosity sample, and other 2 groups all show as very small amount serum
Sample sepage, wherein test group integration is less than positive controls；Treating the 10th day, negative control group still has a small amount of sepage, and other are two years old
Group wound surface tends to healing, and inflammation is inconspicuous, and wherein test group is better than positive controls.
Rat wound inflammation integral contrast respectively organized by table 2
Note: compare with negative control group, p < 0.01；Compare with positive controls, p < 0.05.
(3) wound surface I/ III Collagen Type VI ratio measuring
I in skin, III Collagen Type VI content are higher, based on III Collagen Type VI in wound repair, when collagen newborn in collagen
During increase, I, III Collagen Type VI ratio reduce.This experimental result is shown in Table 3, and result is visible, and 3 groups of ratios are the most on a declining curve, hence it is evident that examination
Test group reduction to become apparent from.
Wound surface I/ III Collagen Type VI ratio measuring table respectively organized by table 3
Note: compare with negative control group, p < 0.01；Compare with positive controls, p < 0.05.
Result above is visible, and somatomedin associating Sanguis Draxonis remarkably promotes wound healing effect for wound repair, suppression
The complication such as inflammation occur, and the stable performance of this preparation, therapeutic effect is notable.
Two, preparation is investigated for diabetic skin ulcer therapeutical effect
1. sample: treatment group: the moist dressing prepared according to the present embodiment 3, and EGF gel group (without Sanguis Draxonis, other groups
Divide with embodiment 3), Sanguis Draxonis group (without somatomedin, other components are with embodiment 3)；
2. animal: healthy adult SD rat 30, body weight 200-250g, male and female half and half.
3. operation:
Modeling dissolves streptozotocin (STZ) with the citrate buffer of the 0.1mmol/L of pH4.6, is made into 1% solution,
Choose 42 SD rats with 60mg/kg continuous 3d intraperitoneal injection induced diabetes, tail vein blood and collect urine after injection 3d
Liquid, by traditional oxydase reaction detection blood sugar level.Blood sugar level after induction > 16.7mmol/L time, i.e. can be considered diabetes
Model is successfully established.Choose the successful rat of modeling 36 and make diabetic skin ulcer model, by diabetes rat with 3% penta
Barbital sodium solution 30mg/kg intraperitoneal injection of anesthesia, back cropping, with 75% ethanol sterilization, do diameter in vertebra both sides
The circular labelling of 15mm, surgically excision mark full thickness skin, after hemostasis with sterile gauze cover, diabetes skin
Skin Ulcer Models.36 diabetic skin ulcer model flood are randomly divided into experimental group, Sanguis Draxonis group, EGF group, often organize 12
Only.Cover wound surface with corresponding dressing, change dressings every day 1 time, 2 weeks courses for the treatment of.
Evaluate ulcer healing area observation: each treated animal respectively at wound after the 3rd, 7,10,14 days, create with transparent plastic mulching
Face is drawn film, is cut film, weighs and is converted into area.
Statistical method spss13.0 statistical software carries out statistical analysis, data withRepresenting, P≤0.05 is for poor
Different statistically significant.
4. result:
(1) ulcer surface healing area the results are shown in Table shown in 4.
Treatment group wound surface area reduces substantially fast compared with other 2 groups, and Sanguis Draxonis group is faster than EGF group Healing Rate, compares with EGF group
Relatively, p < 0.05；Comparing with Sanguis Draxonis group, p < 0.05 difference is statistically significant.
Ulcer wound surface healing area respectively organized by table 4
Therapeutic effect to diabetic skin ulcer is used in combination from result, Sanguis Draxonis and somatomedin and is better than single group
Point, clinical application there is is directive significance.
It will be apparent to those skilled in the art that can technical scheme as described above and design, make other various
Corresponding change and deformation, and all these change and deformation all should belong to the protection domain of the claims in the present invention
Within.
Claims (10)
1. a moist dressing for skin wound, it includes the Sanguis Draxonis of following components: 0.05-0.3wt%, 0.0001-
The epidermal growth factor of 0.001wt%, the gel-type vehicle of 1-5wt%, the wetting agent of 2-10wt%, the penetrating agent of 0.5-5wt%,
The antibacterial of 0.01-2wt%, surplus is water for injection.
The moist dressing of skin wound the most according to claim 1, it is characterised in that: described Sanguis Draxonis is that Sanguis Draxonis surpasses
Micropowder, the particle diameter of described Sanguis Draxonis superfine powder is not more than 10 μm.
The moist dressing of skin wound the most according to claim 1, it is characterised in that: described epidermal growth factor is selected from
One or both in recombinant human epidermal growth factor and fibroblast growth factor, the quality of described epidermal growth factor is dense
Degree is 1000-10000IU/ml.
The moist dressing of skin wound the most according to claim 1, it is characterised in that: described gel-type vehicle is selected from hydroxyl first
One or more in base cellulose, hypromellose, carbomer and hyaluronic acid sodium.
The moist dressing of skin wound the most according to claim 1, it is characterised in that: described wetting agent be glycerol and/
Or propylene glycol.
The moist dressing of skin wound the most according to claim 1, it is characterised in that: described penetrating agent is selected from the third two
One or more in alcohol, azone and carbamide.
The moist dressing of skin wound the most according to claim 1, it is characterised in that: described antibacterial is selected from nipalgin
One or more in esters, benzoic acid/sodium benzoate, quaternary ammonium salt-15, nisin and benzalkonium bromide.
The moist dressing of skin wound the most according to claim 1, it is characterised in that: the pH of described moist dressing is
5.5-7.5, uses sodium hydroxide, hydrochloric acid, borate buffer or phosphate buffer regulation.
9. the preparation method of the moist dressing of a skin wound as claimed in claim 1, it is characterised in that: include following
Step:
(1) first use jet mill dry pulverization process Sanguis Draxonis, obtain coarse grain, then use ball mill dry grinding coarse grain, obtain imperial
Sanguis Draxonis superfine powder particle diameter is not more than 10 μm, and dry powder is collected stand-by；
(2) measure the water for injection of formula ratio 40-50%, be heated to 70-90 DEG C, formula ratio gel-type vehicle is added thereto, stirs
Mix until becoming gel-type vehicle；
(3) measure the water for injection of 40-50%, recipe quantity epidermal growth factor, wetting agent, penetrating agent, antibacterial are added it
In, stir；
(4) solution of preparation in (3) is poured in gel-type vehicle prepared by (2), add Sanguis Draxonis ultra micro prepared by step (1)
Powder, stirs and regulates pH to 5.5-7.5；
(4) supply water for injection, stir, fill, obtain moist dressing.
10. the application in preparation treatment skin ulcer medicine of the moist dressing described in any one of claim 1-8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610784318.2A CN106110389A (en) | 2016-08-30 | 2016-08-30 | A kind of moist dressing of skin wound and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610784318.2A CN106110389A (en) | 2016-08-30 | 2016-08-30 | A kind of moist dressing of skin wound and its preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106110389A true CN106110389A (en) | 2016-11-16 |
Family
ID=57273393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610784318.2A Pending CN106110389A (en) | 2016-08-30 | 2016-08-30 | A kind of moist dressing of skin wound and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106110389A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107252456A (en) * | 2017-06-09 | 2017-10-17 | 成都珂萝瑞诗化妆品有限公司 | A kind of swelling reducing and pain easing gel and preparation method thereof |
| CN107648589A (en) * | 2017-11-28 | 2018-02-02 | 苏州汇涵医用科技发展有限公司 | A kind of skin repair gel and preparation method thereof |
| CN108635622A (en) * | 2018-05-15 | 2018-10-12 | 杭州易敏生物医药科技有限公司 | New liquid gauze and its preparation method and application |
| CN111921005A (en) * | 2020-08-29 | 2020-11-13 | 山东百多安医疗器械股份有限公司 | Preparation method of hemostatic and antibacterial dressing containing herba Cephalanoploris extract |
| CN112370243A (en) * | 2020-11-19 | 2021-02-19 | 南京平港生物技术有限公司 | Sterile medical wet repair dressing and preparation method thereof |
| CN113876693A (en) * | 2021-10-25 | 2022-01-04 | 鸳鸯故里(屏南)生态农业科技有限公司 | Pilose antler polypeptide monomer gel preparation for promoting wound healing and preparation method thereof |
| CN114344407A (en) * | 2021-12-21 | 2022-04-15 | 河南宏业保健科技有限公司 | Traditional Chinese medicine composition for treating skin ulcer |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101316618A (en) * | 2005-11-14 | 2008-12-03 | 株式会社大熊 | Sustained release film formulation for healing wound comprising epidermal growth factor |
| CN102380123A (en) * | 2011-09-30 | 2012-03-21 | 四川师范大学 | Collagen membrane medical dressing and preparation method thereof |
| CN103495199A (en) * | 2013-10-08 | 2014-01-08 | 山东赛克赛斯药业科技有限公司 | Hydrogel wound dressing for treating laser cauma and burns and scalds as well as preparation method thereof |
-
2016
- 2016-08-30 CN CN201610784318.2A patent/CN106110389A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101316618A (en) * | 2005-11-14 | 2008-12-03 | 株式会社大熊 | Sustained release film formulation for healing wound comprising epidermal growth factor |
| CN102380123A (en) * | 2011-09-30 | 2012-03-21 | 四川师范大学 | Collagen membrane medical dressing and preparation method thereof |
| CN103495199A (en) * | 2013-10-08 | 2014-01-08 | 山东赛克赛斯药业科技有限公司 | Hydrogel wound dressing for treating laser cauma and burns and scalds as well as preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 朱颉、曹亿、于萌蕾 等: "血竭壳聚糖药膜对大鼠糖尿病创面Wnt/β-catenin信号的影响", 《岭南现代临床外科》 * |
| 潘卫三: "《新制药技术》", 31 October 2004, 化学工业出版社 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107252456A (en) * | 2017-06-09 | 2017-10-17 | 成都珂萝瑞诗化妆品有限公司 | A kind of swelling reducing and pain easing gel and preparation method thereof |
| CN107648589A (en) * | 2017-11-28 | 2018-02-02 | 苏州汇涵医用科技发展有限公司 | A kind of skin repair gel and preparation method thereof |
| CN108635622A (en) * | 2018-05-15 | 2018-10-12 | 杭州易敏生物医药科技有限公司 | New liquid gauze and its preparation method and application |
| CN111921005A (en) * | 2020-08-29 | 2020-11-13 | 山东百多安医疗器械股份有限公司 | Preparation method of hemostatic and antibacterial dressing containing herba Cephalanoploris extract |
| CN112370243A (en) * | 2020-11-19 | 2021-02-19 | 南京平港生物技术有限公司 | Sterile medical wet repair dressing and preparation method thereof |
| CN113876693A (en) * | 2021-10-25 | 2022-01-04 | 鸳鸯故里(屏南)生态农业科技有限公司 | Pilose antler polypeptide monomer gel preparation for promoting wound healing and preparation method thereof |
| CN114344407A (en) * | 2021-12-21 | 2022-04-15 | 河南宏业保健科技有限公司 | Traditional Chinese medicine composition for treating skin ulcer |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106110389A (en) | A kind of moist dressing of skin wound and its preparation method and application | |
| US4725609A (en) | Method of promoting healing | |
| CA2709545C (en) | Topical application and formulation of erythropoietin for skin wound healing | |
| US20070059350A1 (en) | Agents for controlling biological fluids and methods of use thereof | |
| AU2020101591A4 (en) | A thermosensitive gel, preparation method and application thereof | |
| CN101648007B (en) | A pharmaceutical composition for treating ulcer of lower limb and preparation method thereof | |
| CN107184949B (en) | A kind of superficial wound repairs ointment and preparation method thereof | |
| CN1279923C (en) | Human body lubricant of containing fucose and hyaluronic acid, and its prepn. method | |
| CN107184961A (en) | A kind of competent cell renovation agent and preparation method thereof | |
| CN105250696A (en) | Traditional Chinese medicine gel capable of promoting skin wound to heal and preparation method of traditional Chinese medicine gel | |
| CN113041391A (en) | Herba centellae-collagen-containing repairing freeze-dried sponge and preparation method thereof | |
| CN106110369A (en) | A kind of medical composite type hyaluronic acid dressing and preparation method thereof | |
| JP7465610B2 (en) | Use of Polypeptides in the Manufacture of Wound Care Medicaments - Patent application | |
| CN114699513A (en) | Preparation method of scar gel containing yeast recombinant collagen | |
| WO2016090892A1 (en) | Water-soluble gel for treating diabetic foot | |
| CN110227176A (en) | Scar eliminating silicone gel dressing and preparation method thereof | |
| CN101797376A (en) | Preparation method of modified collagen film | |
| US20210260096A1 (en) | Pharmaceutical composition for treating wound or activating skin, containing beta-glucan, glycitin, and 4',6,7-trimethoxyisoflavone | |
| CN106562953B (en) | Application, drug and process for preparing medicine of the hydroxyl radical carthamin yellow carthamus A in the drug of preparation treatment diabetic foot ulcer | |
| CN116712597A (en) | Composite biological dressing and preparation method and application thereof | |
| CN109078172A (en) | A kind of preparation and its application based on autologous tissue | |
| CN108261562A (en) | A kind of Sodium Hyaluronate skin sparing film and its preparation method and application | |
| CN112535690A (en) | Oxygen supply and sterilization integrated ozone eye cleaning and nursing lotion | |
| CN112121146A (en) | A topical gel for treating skin wound, and its preparation method | |
| CN115137751B (en) | Treatment method of platelet-rich plasma and application of platelet-rich plasma in inhibiting striae gravidarum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20201106 Address after: 201613 No. 5, Jing Jing Road, Shanghai, Songjiang District Applicant after: SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY Co.,Ltd. Applicant after: SHANGHAI JIANHUA FINE BIOLOGICAL PRODUCTS Co.,Ltd. Address before: 200000, Huajing Road, Shanghai, Xuhui District, No. 1285 Applicant before: SHANGHAI JIANHUA FINE BIOLOGICAL PRODUCTS Co.,Ltd. |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161116 |